Insights into Pathogenesis of Chronic Spontaneous Urticaria
Clicks: 4
ID: 321222
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.9
/100
4 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #99 of 313 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Chronic spontaneous urticaria (CSU) is a mast cell-mediated inflammatory disease marked by recurrent wheals and/or angioedema in the absence of identifiable external triggers. Once considered idiopathic, CSU is now recognized as a heterogeneous immunological disorder that results in mast cell activation. Two major endotypes have been described: autoallergic (type I) CSU, mediated by IgE autoantibodies directed against self-antigens, and autoimmune (type IIb) CSU, mediated by IgG autoantibodies targeting IgE or FcεRI on mast cells and basophils. Type IIb CSU is associated with higher disease severity, autoimmune comorbidities, low total IgE levels, and reduced responsiveness to antihistamines and omalizumab. Beyond classical autoantibody-mediated mechanisms, increasing evidence supports the contribution of non-IgE-dependent pathways in CSU pathogenesis. These include Mas-related G protein-coupled receptor X2 (MRGPRX2) - mediated mast cell activation, neuroimmune interactions, activation of coagulation and complement cascades, and persistent low-grade inflammation. Alterations of the gut microbiome and impaired barrier function have also been implicated in sustaining systemic immune activation and lowering mast cell activation thresholds in subsets of patients. Recent therapeutic advances, including biologics targeting type 2 inflammation and small-molecule inhibitors of intracellular signaling pathways such as Bruton's tyrosine kinase, highlight the clinical relevance of these mechanistic insights. However, a substantial proportion of patients remain inadequately controlled, underscoring the need for improved biomarkers, refined endotype stratification, and disease-modifying treatment strategies. This review summarizes current insights into the multifactorial pathophysiology of CSU, highlights remaining knowledge gaps, and discusses how emerging concepts may inform more precise, personalized, and potentially disease-modifying therapeutic approaches.
| Reference Key |
openalex_W7168419516
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Torsten Zuberbier, Hanna Bonnekoh, Emek Kocatürk, Pavel Kolkhir, Leonard Lionnet, Melba Muñoz, Katarina Stevanovic, Martin Metz |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag277
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.